|
|||||
|
|
A panel discussion of controversies and challenges in the adjuvant treatment of colon cancer |
|
| Authors: | Eduardo Díaz-Rubio García Albert Abad Esteve Antonio Antón Torres Enrique Aranda Aguilar Manuel Benavides Orgaz Alfredo Carrato Mena Andrés Cervantes Ruipérez Jaime Feliu Batle Pilar García Alfonso Jesús García Foncillas Cristina Garávalos Castro Matilde Navarro García Fernando Rivera Herrero José María Tabernero Caturla |
| Affiliation: | 1. Service of Medical Oncology, Hospital Universitario San Carlos, Madrid, Spain 3. Service of Medical Oncology, Hospital Universitari Germans Trias i Pujol. Badalona, Barcelona, Spain 4. Service of Medical Oncology, Hospital Miguel Servet, Zaragoza, Spain 5. Service of Medical Oncology, Hospital Reina Sofia, Córdoba, Spain 6. Service of Medical Oncology, Hospital General Carlos Haya, Málaga, Spain 7. Service of Medical Oncology, Hospital General Universitario de Elche, Elche. Alicante, Spain 8. Service of Medical Oncology, Hospital Clínico Universitario, Valencia, Spain 9. Service of Medical Oncology, Ciudad Sanitaria La Paz, Madrid, Spain 10. Service of Medical Oncology, Hospital General Universitario Gregorio Mara?ón, Madrid, Spain 11. Laboratory of Biotechnology and Pharmacogenomics, Clínica Universitaria de Navarra, Pamplona, Spain 12. Service of Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain 13. Service of Medical Oncology. Institut Català d'Oncologia (ICO), L'Hospitalet de Llobregat, Barcelona, Spain 14. Service of Medical Oncology, Hospital Universitario Marqués de Valdecilla, Santander, Spain 15. Service of Medical Oncology, Hospital General Vall d'Hebron, Barcelona, Spain |
| Abstract: | Current issues of adjuvant therapy for colon cancer concern the introduction of drugs other than fluorouracil-5/leucovorin (5-FU/LV), the benefits for stage II patients, the use of new primary endpoints and the influence of age on treatment benefits. These issues were addressed in a panel discussion and the conclusions were the following: FOLFOX4 is the first regimen that shows superiority over 5-FU/LV. The use of 3-year disease-free survival as primary endoint could encourage the quicker adoption of improved therapeutic strategies into clinical practice. Available data suggest that there are some benefits for stage II patients, and the decision needs to be individualised for each patient. Further, therapeutic decisions based solely on the patient's age are inappropriate, and geriatric assessment tools will help in making this decision. This information would improve patient and physician understanding of the recent data regarding the potential benefits of adjuvant therapy. |
| Keywords: | adjuvant treatment colon cancer |
| 本文献已被 SpringerLink 等数据库收录！ | |